Stock Ratings / Health Care / ARTL / dividends

SPRC (55) GNPX (47) OGEN (44) PPBT (61) ⌘ Pro Terminal →

Artelo Biosciences Inc. (ARTL) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is ARTL trading relative to its 50-day, 200-day, and 52-week technical levels?

ARTL last traded at $2.22 (-3.90% on volume of 12,436 shares), positioning the stock -48.25% below its 50-day simple moving average ($4.29) and -89.80% below its 200-day simple moving average ($21.77). Across its 52-week range of $2.05 to $179.19, ARTL sits at the 0.1% percentile with a 14-day RSI of 28.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.94 to $2.50).

Q: Does ARTL pay a dividend and is it safe?

Artelo Biosciences Inc. (ARTL) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$2.22 -3.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.20

Artelo Biosciences Inc. (ARTL) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARTL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Artelo Biosciences Inc. (NASDAQ: ARTL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $2.22 (-3.90% 1D, market cap $1.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTL ranks #518 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARTL compare to SPRC and GNPX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARTL carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRC (SciSparc Ltd.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $1.5M) and GNPX (Genprex Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, ARTL leads on earnings multiple (N/A) while ARTL leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARTL?

▼

Per ARTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001621221), Artelo Biosciences Inc. generated $0 in revenue, -$12.9M in net income, and -$8.5M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.20 (-0.89%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARTL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY ARTL SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.9 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.26-17.2% Next Q

Q2 (-2Q)

Grade D$2.70-5.6% Next Q

Q3 (-1Q)

Grade D$2.55-12.9% Next Q

Current

Grade D-$2.22-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ARTL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ARTL currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.29) and Max Pain ($2.33) forces dealer call-delta covering toward $188.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARTL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ARTL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARTL)

✓Walkthrough of ARTL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ARTL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -92.93%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.25H $2.29L $2.18C $2.22VOL 12.0K

RES: $18.25SUP: $0.73SMA50: $4.29SMA200: $21.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARTL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARTL Butterfly Map → + Track ARTL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARTL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARTL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ARTL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARTL)

Health Care Rank #518 of 1016 ⚔️ SPRC vs ARTL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARTL vs. SPRC, GNPX, OGEN, PPBT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Artelo Biosciences Inc. (ARTL) ranks #518 by composite RQD confidence (41/100, grade D-) and #1015 by equity capitalization ($1.3M). Within this direct 5-issuer industry benchmark cohort, ARTL leads on earnings valuation at N/A trailing P/E, while ARTL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with ARTL at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ARTL ACTIVE Artelo Biosciences Inc.	D-	41/100	—	—	-35.0%	-3.90%	$1.3M	Benchmark Subject
SPRC SciSparc Ltd.	D+	55/100	—	—	—	-5.05%	$1.5M	/sprc-vs-artl →
GNPX Genprex Inc.	D	47/100	—	—	-35.0%	+9.80%	$1.7M	/gnpx-vs-artl →
OGEN Oragenics Inc.	D	44/100	—	—	-35.0%	-0.05%	$1.7M	/ogen-vs-artl →
PPBT Purple Biotech Ltd.	C-	61/100	—	—	—	+7.34%	$1.8M	/ppbt-vs-artl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001621221

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artelo Biosciences Inc. (ARTL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.9M, operating cash flow of -$8.5M, and free cash flow of -$8.5M (-2.0% YoY). On the balance sheet, ARTL closed FY2025 with $2.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.9M	-$8.5M	-$8.5M	$2.8M	—
FY2024 (FY)	2024-12-31	$0	-$9.8M	-$8.3M	-$8.3M	$4.7M	—
FY2023 (FY)	2023-12-31	$0	-$9.3M	-$8.2M	-$8.2M	—	—

3. ARTL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ARTL compare to SPRC and GNPX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ARTL?

Where is ARTL trading relative to its 50-day, 200-day, and 52-week technical levels?

ARTL last traded at $2.22 (-3.90% on volume of 12,436 shares), positioning the stock -48.25% below its 50-day simple moving average ($4.29) and -89.80% below its 200-day simple moving average ($21.77). Across its 52-week range of $2.05 to $179.19, ARTL sits at the 0.1% percentile with a 14-day RSI of 28.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.94 to $2.50).

ARTL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ARTL pay a dividend and is it safe?

Artelo Biosciences Inc. (ARTL) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ARTL RQD Cockpit ARTL 12M Forecast ARTL Earnings & Move ARTL Dividends & DRIP ARTL Insiders & 13F ARTL Whale Options ARTL Profit Sankey ARTL News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ARTL — Artelo Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:21Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Artelo Biosciences Inc. (ARTL) carries a composite score of 41/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $2.22 (-3.90%). Fundamental cash generation scores 8/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 8/20, insider conviction scores 5/20, macro regime alignment scores 10/20 (Beta 1.00), and forensic balance-sheet protection scores 10/20 (Altman Z-Score N/A, Piotroski F-Score 1/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $2.05 – $179.19.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ARTL is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

ARTL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Artelo Biosciences Inc. (ARTL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ARTL Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 4d ago

Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain

Nonclinical studies demonstrated reductions in two key measures of neuropathic pain Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple cancer-related symptoms SOLANA

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 4d ago

Artelo Biosciences To Present Data For Its ART27.13 To Treat Chemotherapy-Induced Neuropathic Pain At IASP 2026 World Congress On Pain

Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 7d ago

Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain

Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports ART26.12’s potential as a no

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 7d ago

Artelo Bioscience To Present Data On ART26.12 Program At IASP 2026 World Congress On Pain, October 26–30; Growing Body Of Data Supports ART26.12’s Potential As A Novel, Non-Opioid Treatment For Pain Ahead Of Planned Multiple Ascending Dose Study

Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 26d ago

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications BIO-Europe provides a key platform to advance ongoing discussions and expa

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 40d ago

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s int

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 67d ago

Artelo Biosciences Announces Reverse Stock Split

Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage p

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 77d ago

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (N

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARTL Bull vs. Bear Conversation Board — What's Your Call at $2.22?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARTL 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.95 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ARTL (D- • RQD 41/100) a Buy at $2.22?

Welcome to the ARTL (Artelo Biosciences Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.75 (-21.2%)

Spot @ $2.22

Pump the brakes on ARTL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ARTL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Artelo Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.53 (+14.0%)

Spot @ $2.22

ARTL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ARTL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.22 (52-wk range $2.05 - $179.19), any beat on forward guidance forces shorts and underweight funds to chase.